Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price objective lifted by stock analysts at SunTrust Banks, Inc. to $116.00 in a research note issued to investors on Wednesday. The brokerage presently has a “positive” rating on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s price objective would suggest a potential upside of 35.40% from the company’s previous close.
SAGE has been the topic of several other reports. BidaskClub lowered Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. J P Morgan Chase & Co cut their price target on Sage Therapeutics from $99.00 to $85.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 12th. Chardan Capital reissued a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, September 13th. Cowen and Company reissued a “buy” rating and set a $100.00 price target on shares of Sage Therapeutics in a research note on Friday, August 4th. Finally, Royal Bank Of Canada lifted their price target on Sage Therapeutics from $117.00 to $120.00 in a research note on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Sage Therapeutics has an average rating of “Buy” and a consensus target price of $105.71.
Sage Therapeutics (NASDAQ SAGE) traded up $0.20 during trading hours on Wednesday, reaching $85.67. The company had a trading volume of 768,400 shares, compared to its average volume of 544,300. Sage Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $99.80.
Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts predict that Sage Therapeutics will post -7.36 EPS for the current fiscal year.
WARNING: This piece of content was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/11/17/suntrust-banks-inc-increases-sage-therapeutics-inc-sage-price-target-to-116-00.html.
Several institutional investors and hedge funds have recently modified their holdings of SAGE. Bank of New York Mellon Corp raised its position in shares of Sage Therapeutics by 36.5% during the third quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after acquiring an additional 724,494 shares during the last quarter. BlackRock Inc. increased its holdings in Sage Therapeutics by 5.9% in the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock worth $241,431,000 after purchasing an additional 168,424 shares in the last quarter. New York State Common Retirement Fund increased its holdings in Sage Therapeutics by 258.0% in the third quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock worth $9,318,000 after purchasing an additional 107,782 shares in the last quarter. Farallon Capital Management LLC bought a new stake in Sage Therapeutics in the second quarter worth approximately $7,964,000. Finally, Pioneer Investment Management Inc. increased its holdings in Sage Therapeutics by 126.9% in the second quarter. Pioneer Investment Management Inc. now owns 158,418 shares of the biopharmaceutical company’s stock worth $12,616,000 after purchasing an additional 88,585 shares in the last quarter.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.